Tempus
Cancer patients wanting AI-matched treatment options
Prices verified Aug 13, 2026 on Tempus's own site
Test Performance
Sensitivity
N/A
Specificity
N/A
Detection Method
Genomic + AI
Turnaround
10-14 days
Key Features
Largest genomic database • AI-powered insights • Clinical trial matching • Liquid + tissue options
Who It's For
Suited to: Cancer patients wanting AI-matched treatment options
Not suited to: Initial cancer screening
This test is ordered by an oncologist after a cancer diagnosis. It is not a screening test for people without cancer. See the screening tests.
Important Notes
Combines genomic testing with AI for treatment recommendations. xT CDx is an FDA-approved 648-gene tissue assay; the FDA approved the tumor-only indication in May 2026, making Tempus the first lab with CDx approval for both tumor-only and tumor-normal comprehensive genomic profiling. Liquid biopsy options: xF (105 genes) and xF+ (523 genes), 7-9 day turnaround.